Experimental cell research · 2026
RET inhibition by selpercatinib suppresses TGF-β1-induced epithelial-mesenchymal transition in retinal pigment epithelium.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Meilan, Zhao Rui, Chen Xiaohui, Xu Lu, Hu Chun
Аннотация
PURPOSE: The transforming growth factor-β (TGF-β) pathway is a master regulator of epithelial-mesenchymal transition (EMT) in retinal pigment epithelial (RPE) cells, a key process in fibrotic ocular diseases. However, key modulators fine-tuning this pathway in RPE are incompletely characterized. This study investigates the role of the receptor tyrosine kinase RET in TGF-β1-induced RPE-EMT.
METHODS: The role of RET was assessed in vitro using the clinically approved RET inhibitor, Selpercatinib, in RPE cells stimulated with TGF-β1. Outcomes included EMT markers, migration, proliferation, and transcriptional reprogramming. Key downstream signaling effectors Smad3 and ERK were analyzed. In vivo validation was performed in mouse models of TGF-β1-induced EMT and sodium iodate (NaIO3)-induced RPE injury.
RESULTS: Pharmacological inhibition of RET with Selpercatinib effectively suppressed TGF-β1-induced EMT, migration, proliferation, and associated transcriptional reprogramming in RPE cells. Mechanistically, RET kinase activity was required for the TGF-β1-induced activation of Smad3 and ERK. In mouse models, Selpercatinib treatment attenuated RPE-EMT and preserved retinal structure.
CONCLUSIONS: Our findings establish RET as a critical modulator in the TGF-β signaling pathway in RPE cells and highlight the therapeutic potential of repurposing RET inhibitors for the treatment of fibrotic retinal diseases.
METHODS: The role of RET was assessed in vitro using the clinically approved RET inhibitor, Selpercatinib, in RPE cells stimulated with TGF-β1. Outcomes included EMT markers, migration, proliferation, and transcriptional reprogramming. Key downstream signaling effectors Smad3 and ERK were analyzed. In vivo validation was performed in mouse models of TGF-β1-induced EMT and sodium iodate (NaIO3)-induced RPE injury.
RESULTS: Pharmacological inhibition of RET with Selpercatinib effectively suppressed TGF-β1-induced EMT, migration, proliferation, and associated transcriptional reprogramming in RPE cells. Mechanistically, RET kinase activity was required for the TGF-β1-induced activation of Smad3 and ERK. In mouse models, Selpercatinib treatment attenuated RPE-EMT and preserved retinal structure.
CONCLUSIONS: Our findings establish RET as a critical modulator in the TGF-β signaling pathway in RPE cells and highlight the therapeutic potential of repurposing RET inhibitors for the treatment of fibrotic retinal diseases.